by reason for retraction – Page 7

High-profile ob-gyn accused of duplicating data threatens to sue critic

Sometime last summer, Ben Mol, an obstetrician-gynecology researcher in Australia, and his colleagues were adapting a European guideline on unexplained infertility when they came across a 2006 paper from Maria Luisa Casini, a pharmacologist in Rome, that gave them pause because of results that were not statistically significant.

When they looked further, they ended in a rabbit hole. Casini’s previous work revealed identical patient data across papers published two years apart, despite purporting to come from different groups of patients. The similarities were striking: In the 2006 paper, the women’s mean height was 165.5 centimeters; in the study published two years earlier that reported having more than triple the number of participants, the women had the exact same mean height, with the same standard deviation.

The guideline update would eventually lead to half of the included trials being flagged for integrity issues, and as a result, left out of the Australian version of the guideline. From that one paper by Casini that had initially raised doubts, the team was able to unearth a trail of suspicious data connected to several ob-gyns in Italy. An Italian medical society and one of the implicated authors have threatened to sue over the allegations, claiming the complaints were made to interfere with a high-profile society election, but the papers are now part of a wider Elsevier investigation.

Paper claiming vaping tops nicotine gum for smoking cessation retracted from JAMA journal

A JAMA journal has retracted a paper on vaping it published two months ago after the researchers alerted the editors to “significant coding errors” and other problems with the work.

The article, “Efficacy of Electronic Cigarettes vs Varenicline and Nicotine Chewing Gum as an Aid to Stop Smoking: A Randomized Clinical Trial,” was written by a group from China led by Zhao Liu, of the Department of Tobacco Control and Prevention of Respiratory Disease at China-Japan Friendship Hospital, in Beijing.

According to the researchers, the study found use of vapes was no worse than a prescription medication, and better than nicotine gum, at helping people quit smoking.

The paper received a significant amount of attention in the medical and lay press and on social media (full disclosure: Medscape, where Adam works, covered it).

Here’s the March 29 retraction notice for the paper, which originally appeared online in JAMA Internal Medicine January 29:

Paper cited by article at center of lawsuit for criticizing Splenda earns an expression of concern

A journal has issued an expression of concern for a 2008 paper suggesting artificial sweetener Splenda could disrupt the gut microbiome and cause other havoc with the gastrointestinal system – and which is cited by a paper at the center of a lawsuit against one of its authors by the maker of the sugar substitute.

The article, “Splenda Alters Gut Microflora and Increases Intestinal P-Glycoprotein and Cytochrome P-450 in Male Rats,” appeared in the Journal of Toxicology and Environmental Health, Part A, a Taylor & Francis title. The journal has a Part B, too, which also is part of this story.

The paper, which has been cited more than 200 times, according to Clarivate’s Web of Science, caught the attention of Elisabeth Bik, who last year commented on the article on PubPeer, noting potential problems with four of the figures, including Western blots and missing error bars.

Rejected paper pops up elsewhere after one journal suspected manipulation

In the autumn of 2022, a researcher in Turkey was reviewing a paper for a cardiology journal when an image of a Western blot caught her eye: A hardly visible pair of “unusual” lighter pixels seemed out of place. Magnification only bolstered her suspicion that something was off.

“This image made me think that the bands were cut one by one and pasted on a membrane background,” Şenay Akin, of Hacettepe University in Ankara, wrote in her comments to the editor of Cardiovascular Drugs and Therapy, a Springer Nature journal. “If this is the case, it indicates a manipulation [of] the results of this study.”

The editor, Yochai Birnbaum of Baylor College of Medicine in Houston, Texas, made a note to check the figure, adding below Akin’s comments in the editorial-management system: “I agree with the reviewer. It could be that the I/R band was manipulated.”

Misspelled cell lines take on new lives — and why that’s bad for the scientific literature

Human cell lines represent key reagents for many research laboratories. Cell lines are often the first models that researchers choose for experiments such as gene manipulation and drug testing, as they are relatively accessible and inexpensive, particularly compared with mouse and other animal models.

However, cell lines also are prone to contamination by other faster growing cell lines. As a result, many human cell lines purported to represent particular tumor types have been found by genetic testing to be contaminated by other cancer cells. This potential for confusion poses a serious problem for researchers who want to study a particular cancer type but end up using cells from an unrelated disease.

Our team studies wrongly identified nucleotide sequence reagents in cancer research, such as PCR primers and gene knockdown reagents. Recently in the context of an undergraduate student project, we decided to also check the identities of cell lines in a small group of papers on the human gene miR-145, which codes for a microRNA. We found wrongly identified nucleotide sequences and cell lines in numerous articles about miR-145, but also what appeared to be five misspelled identifiers of contaminated cell lines.

Cancer paper earns expression of concern nearly two years after investigation report is revealed

A Springer Nature journal has issued an expression of concern for a 16-year-old paper by Carlo Croce, the cancer researcher – and noted art collector – at The Ohio State University three years after the publication had received a correction for problematic images and roughly 20 months after the news division at Nature reported on a pair of institutional investigations into problems with Croce’s work.

As we and others have reported, those investigations concluded Croce had not committed misconduct but had overlooked the misdeeds of others in his lab.

Here’s the notice for the paper, “MicroRNA signatures of TRAIL resistance in human non-small cell lung cancer,” which Oncogene published in 2008:

KPMG government report on research integrity makes up reference involving Retraction Watch founders

An August 2023 report on research integrity by consulting firm KPMG, commissioned by an Australian government agency, contains a made-up reference, Retraction Watch has discovered.

Reference 139 of the report, “International Research Integrity Policy Scan Final Report: Compilation of information about research integrity arrangements outside Australia,” reads:

Gunsalus CK, Marcus AR, Oransky I, Stern JM. Institutional and individual factors that promote research integrity. In: Macrina FL, editor. Scientific Integrity: Text and Cases in Responsible Conduct of Research. 4th ed. Washington, DC: ASM Press; 2018. p. 53-82.

A book with that title exists, but the four authors listed did not contribute a chapter, and the 2018 edition does not appear to contain a chapter with that title. We – Adam Marcus and Ivan Oransky – have indeed published with CK Gunsalus, but nothing resembling this reference.

Exclusive: Embattled dean accused of plagiarism in NSF report

Erick Jones, the dean of engineering at the University of Nevada in Reno, appears to have engaged in extensive plagiarism in the final report he submitted to the National Science Foundation for a grant, Retraction Watch has learned.

The $28,238 grant partially supported a three-day workshop that Jones and his wife, Felicia Jefferson, held for 21 students in Washington, DC, in April 2022 titled “Broadening Participation in Engineering through Improved Financial Literacy.” Jefferson received a separate award for $21,757.

Jones submitted his final report to the agency in May 2023. Retraction Watch obtained a copy of that report through a public records request to Jones’s previous employer, the University of Texas at Arlington, and identified three published sources of extended passages he used without citation or quotation marks.

A cardiac surgeon’s tortuous efforts – including three lawsuits – to get the scientific record corrected

For the past 14 years, a cardiac surgeon in Italy has been trying to blow the whistle on a study written by his former colleagues that has been the subject of several investigations – with two of them finding problems with the data. And despite defeating three defamation lawsuits, two which were brought by authors of the paper, he’s not giving up yet.

The 2006 paper, ‘Relationship between atrial histopathology and atrial fibrillation after coronary bypass surgery’, written by several of cardiac surgeon Vittorio Mantovani’s colleagues at the Ospedale di Circolo in Varese, was published in the Journal of Thoracic and Cardiovascular Surgery. To date, the paper – which has been cited 57 times, according to Clarivate’s Web of Science – has been investigated by at least two institutions as well as the journal. None have resulted in a retraction, despite one university finding that only a little more than half of the patients in the dataset could be matched unambiguously with biopsy samples. One university is also waiting on the journal to act before it considers reopening its own investigation.

For Mantovani, the red flags started appearing in 2010, when he came across a minor discrepancy between two other papers written by him and his colleagues. He thought it was odd that in one dataset, patients were identified by name, but in the other, they were identified using numbers.

Medical society takes millions from company that sued it for defamation – and lost

When the American Society of Anesthesiologists last October announced the receipt of a $2.5 million donation from a drug company – “to advance education and innovation for our members” – the news could have been dismissed with a shrug. After all, such gifts from industry to medical societies are commonplace.

What makes this case noteworthy is that until the donation, the ASA and the drug maker, Pacira BioSciences, were better known as adversaries embroiled in a bitter lawsuit over three articles about the company’s flagship product the society had published in 2021 in its main scientific journal.

The papers, which questioned the effectiveness of Exparel, an anesthetic intended for the treatment of patients undergoing orthopedic surgery and other procedures. As we reported in May 2021, as part of a larger suit against the ASA, Pacira demanded in legal filings that the ASA and its journal, Anesthesiology, retract the papers, which it considered libelous.

The company didn’t hold that stance long, however. We wrote then:

Share this:

Share this:

Share this:

Share this:

Share this:

Share this:

Share this:

Share this:

Share this:

Share this: